Decrease of pro-angiogenic monocytes predicts clinical response to anti-angiogenic treatment in patients with metastatic renal cell carcinoma

Stephane Oudard, Nadine Benhamouda, Bernard Escudier, Patrice Ravel, Thi Tran, Emeline Levionnois, Sylvie Negrier, Philippe Barthelemy, Jean François Berdah, Marine Gross-Goupil, Cora N. Sternberg, Petri Bono, Camillo Porta, Ugo De Giorgi, Omi Parikh, Robert Hawkins, Martin Highley, Jochen Wilke, Thomas Decker, Corinne TanchotAlain Gey, Magali Terme, Eric Tartour

Research output: Contribution to journalArticlepeer-review

Abstract

The modulation of subpopulations of pro-angiogenic monocytes (VEGFR-1+ CD14 and Tie2+ CD14) was analyzed in an ancillary study from the prospective PazopanIb versus Sunitinib patient preferenCE Study (PISCES) (NCT01064310), where metastatic renal cell carcinoma (mRCC) patients were treated with two anti-angiogenic drugs, either sunitinib or pazopanib. Blood samples from 86 patients were collected prospectively at baseline (T1), and at 10 weeks (T2) and 20 weeks (T3) after starting anti-angiogenic therapy. Various subpopulations of myeloid cells (monocytes, VEGFR-1+ CD14 and Tie2+ CD14 cells) decreased during treatment. When patients were divided into two subgroups with a decrease (defined as a >20% reduction from baseline value) (group 1) or not (group 2) at T3 for VEGFR-1+ CD14 cells, group 1 patients presented a median PFS and OS of 24 months and 37 months, respectively, compared with a median PFS of 9 months (p = 0.032) and a median OS of 16 months (p = 0.033) in group 2 patients. The reduction in Tie2+ CD14 at T3 predicted a benefit in OS at 18 months after therapy (p = 0.04). In conclusion, in this prospective clinical trial, a significant decrease in subpopulations of pro-angiogenic monocytes was associated with clinical response to anti-angiogenic drugs in patients with mRCC.

Original languageEnglish
Article number17
JournalCells
Volume11
Issue number1
DOIs
Publication statusPublished - Jan 1 2022

Keywords

  • Angiogenesis
  • Biomarker
  • Myeloid cells
  • Pro-angiogenic monocytes
  • Renal cell carcinoma

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint

Dive into the research topics of 'Decrease of pro-angiogenic monocytes predicts clinical response to anti-angiogenic treatment in patients with metastatic renal cell carcinoma'. Together they form a unique fingerprint.

Cite this